Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Professor Riedemann's company was founded to translate complement system research into clinical applications, aiming to improve patient care. The pandemic shifted healthcare priorities, but focus is ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

From an early age, Dr. Kelli Crabtree-Wilson was fascinated by the human nervous system. Personal experiences sparked her ...

The denim supply chain officially kicked off the Spring/Summer 2027 season last week at Kingpins Amsterdam.

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...

Gamification is now a $19 billion industry, which still has lots of growth potential. One organization that is using it for ...

GFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients 1-3 Fabhalta is first and only approved complement inhibitor for ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria ...

Closing legal loopholes that allow deforestation-linked products to enter markets and getting international lenders to align funding with environmental goals are key to ending deforestation, says Erin ...

Alert systems, also known as trigger-based systems, provide a critical advantage over raw data delivery approaches by ...